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ABSTRACT 
 
Basal forebrain cholinergic neurons (BFCNs) of the medial septal nuclei, 
the diagonal bands of Broca and the nucleus basalis magnocellularis synthesize 
acetylcholine (ACh) and their projections extend to the cerebral cortex, 
hippocampus and the amygdala.  ACh neurotransmission is essential for 
learning, attention, memory, arousal and sleep.  BFCNs are dependent on a 
regulated neurochemical environment for the induction, development, maturation 
and maintenance of their phenotype and viability.  However, events that 
compromise this neurochemical environment can contribute to BFCN dysfunction 
and/or degeneration, decreased ACh levels and disrupted brain function. During 
normal aging and Alzheimer’s disease (AD) BFCNs become more vulnerable to 
dysfunction due to trophic factor withdrawal, cell signaling impairments and other 
cytopathologic changes. AD is characterized by the deposition of Amyloid-beta 
(Aβ) plaques and neurofibrillary Tau tangles (NFTs) in the cortex and 
hippocampus.  These pathological AD hallmarks overlap with cortical and 
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hippocampal cholinergic dysfunction, implicating both as the drivers of cognitive 
and behavioral decline associated with AD.  Since, BFCNs are highly vulnerable 
to AD pathophysiology, factors that support the BFCN phenotype may have 
practical use in preserving neuronal networks and cognitive function.   
There is now strong evidence that bone morphogenetic protein-9 (BMP9 
also known as growth/differentiating factor 2, GDF2) acts as an induction and 
maintenance factor that regulates BFCN differentiation in-vitro and in-vivo.  Here 
we used transgenic mice that express green fluorescent protein (GFP) in BFCNs 
to make observations concerning the BFCN phenotype in aging and AD.   We 
found qualitative evidence that BFCNs of the 24-month old WT/ChAT-GFP mice 
were smaller and more rounded with shorter processes when compared to 6-
month old mouse BFCNs.  We analyzed the effects of intracerebroventricular 
infusion of BMP9 on BFCN projection fibers in the APPswe/PS1dE9 mouse 
model of AD using laser scanning confocal microscopy.   BMP9 not only 
increased the density of cholinergic projection fibers in the hippocampus of wild 
type and AD model APPswe/PS1dE9 mice, but it also reduced the plaque burden 
in the hippocampus of the AD mouse model. These data indicate that BMP9 
ameliorated two major pathophysiologic hallmarks of AD, observable in these 
transgenic APPswe/PS1dE9 mice.  BMP9 reduced Aβ plaque burden in this AD 
model, and enhanced the outgrowth and viability of cholinergic fibers within the 
hippocampus of both wild-type and APPswe/PS1dE9 mice.   
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Prior studies in our laboratory identified 300 genes differentially expressed 
in the BFCNs purified from APPswe/PS1dE9 mice as compared to their wild type 
littermates.  One of these, the cellular prion protein (PrPc), displayed a 2.8-fold 
increase in mRNA expression in APPswe/PS1dE9 mice over wild-type controls.  
Our analysis of PrPc expression by quantitative immunohistochemistry revealed a 
46% increase in the number of BFCNs expressing PrPc protein medial septum 
and vertical and horizontal limbs of the diagonal band of Broca (p=0.0007), but 
not in the striatum of the APPswe/PS1dE9 model of AD.  Recently, studies have 
shown that direct binding of PrPc is required for Aβ neurotoxicity, synaptic 
impairment and cognitive dysfunction.  Based on our results as well as others, it 
is possible that high PrPc expression in the BFCNs could be responsible for at 
least part of the cholinergic deficits observed in AD.  Studies have also shown 
that PrPc is a receptor for Aβ and that this Aβ-PrPc interaction leads to pathologic 
tau phosphorylation and toxicity providing evidence that all three major 
hypotheses of AD: the Aβ-hypothesis, the tau hypothesis and the cholinergic 
hypothesis converge toward PrPc.  
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PREFACE 
The brain is composed of billions of highly organized glial cells and 
neurons that receive, integrate, store and export information to interconnected 
subpopulations of neurons.  It is the command center of the organism that 
processes a wide variety of sensorimotor stimuli and higher executive functions 
such as cognition, memory, and emotions that govern behavior. Brain regions 
that control these functions and the subpopulations of neurons residing therein 
can be distinguished by their molecular and morphological characteristics.  
These phenotypic traits are established by specific gene expression profiles 
which direct the differentiation and maturation of individual neuronal subclasses.  
For example, basal forebrain cholinergic neurons can be distinguished by a 
specific structural morphology and molecular phenotype.  The functional extent of 
the cholinergic system can be observed in many diverse locales throughout the 
vertebrate organism including the central nervous, cardiovascular, digestive, 
respiratory and motor systems. Thus a comprehensive understanding of the 
cholinergic network is essential in understanding organismal biology.  Here, this 
study focuses on the basal forebrain cholinergic neurons and their fibers located 
in an area of central nervous system long known to be affected by AD.  Initially, I 
will synthesize a comprehensive background review on the developmental, 
anatomical and molecular phenotype of cholinergic neurons in the basal 
forebrain.  Results pertaining to the molecular and morphological analyses of 
BFCNs as a function of aging and AD-like pathology, were obtained using a 
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combination of immunohistochemistry and confocal microscopic techniques.  If 
these initial discoveries are consistent and repeatable, they may contribute to the 
development and implementation of a safe and useful intervention for AD. 
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INTRODUCTION 
  
The neuroanatomical development of the basal forebrain cholinergic 
nuclei and their projection pathways result from highly orchestrated 
morphogenetic, cell-to-cell and autocrine/paracrine signaling mechanisms (Dale 
et al., 1997; Sussel et al., 1999).  As a result, cholinergic neurons in the basal 
forebrain differentiate and project their axon terminals to the hippocampus and 
cerebral cortex where they release acetylcholine to modulate neuronal activity.   
Thus the development, maturation and maintenance of the cholinergic system is 
critical for the processes of attention, learning and memory.  
AD leads to dysfunction and degeneration of multiple neuronal subclasses 
in specific brain regions by disrupting normally functioning molecular, cellular, 
local circuits and neuronal networks, including the basal forebrain cholinergic 
network (Palop and Mucke, 2010).   
Three AD hypotheses have been described and each additively 
contributes to the pathological hallmarks of AD: 1) Aβ deposition, 2) 
neurofibrillary tau tangle formation and 3) the cholinergic deficits. 
Accumulating evidence implicates the cellular prion protein, PrPc as a 
factor that promotes AD pathophysiology and that all three hypotheses of AD 
converge at PrPc. We provide evidence that PrPc is upregulated specifically in 
BFCNs which may increase their neuronal susceptibility during AD pathological 
progression.  
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Since BFCNs are essential for memory and cognitive function, exogenous 
application of factors that regulate BFCN development may prove useful in 
generating BFCNs from pluripotent stem cells or by promoting their viability and 
physiological function in brain regions affected by AD.  In support of these ideas, 
we provide strong in-vivo evidence that BMP9, a factor that promotes the 
cholinergic neuronal phenotype, can ameliorate two pathophysiological hallmarks 
of AD by reducing Aβ plaques and by increasing cholinergic density in the 
hippocampus.   
These data describe an important concept in potential AD therapies by 
focusing on factors that influence multiple aspects of AD pathology.  Given the 
genetic, environmental and pathophysiological complexities of AD it is highly 
unlikely that there is one magic bullet to slow, stop or prevent the progressive 
nature of the disease. Therapeutic candidates should include those factors with 
potential to reduce more than one AD pathophysiological mechanism.  Since 
PrPc interacts with Aβ, is expressed by BFCNs and may lead to tau 
phosphorylation targeting this protein may ultimately improve AD from three 
angles.  Likewise, by increasing cholinergic innervation and decreasing plaque 
load in the hippocampus, BMP9 was shown to improve AD-like pathology in-vivo 
and highlights the utility of this developmental regulator of the BFCNs as a 
potential AD therapy. 
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BFCN DEVELOPMENT 
BFCN origination and development begins with regional specification of 
the early telencephalon, proliferation and differentiation is then initiated through 
induction, maintenance and maturation signaling mechanisms.  These highly 
conserved patterns of vertebrate telencephalic development are established by 
morphogenetic gradients regulated by growth factors and cytokines which modify 
gene transcription to determine body axes, regional boundaries and the 
differentiation of forebrain cell types (Shimamura et al., 1995; Rubenstein and 
Beachy, 1998).  In general, current developmental models are based on the idea 
that neuronal populations arise from spatio-temporally regulated gene expression 
programs fine-tuned by concentration-dependent patterns or signaling ‘pulses’ 
within the neurochemical niche. Competent embryonic tissues are organized into 
distinct molecular domains to establish transverse and longitudinal borders along 
morphogenetic gradients.  The establishment of the caudal-rostral, dorsal-
ventral, medial-lateral axes by distinct morphological and molecular boundaries 
creates an organized “grid-like” prosomeric model of forebrain development 
(Rubenstein et al., 1994).  This grid-like patterning of forebrain anatomical 
structure is evolutionarily conserved across multiple species of organisms 
including lower mammals, i.e., mice to more complex non-human primates and 
humans from embryogenesis into adult forebrain development (Wedeen et al., 
2012).  
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The axis of patterning in the rostrobasal telencephalon gives rise to 
subpallial proliferative zones of the medial ganglionic eminence (MGE), lateral 
ganglionic eminence (LGE) and the preoptic area (POA) which contribute to 
nearly all forebrain structures such as the cortex, striatum, hippocampus, 
amygdala and septum (Marin et al., 2000; Gelman et al., 2009; Nobrega-Pereira 
et al., 2010).  Migratory cells from each of these three embryonic proliferative 
zones are further classified into septal progenitor domains, SE1-6 (Flames et al., 
2007), which develop into the heterogeneously populated neuronal nuclei located 
in the basal forebrain, in which there are several cholinergic nuclei present.  
Basal forebrain cholinergic neurogenesis in mice occurs between embryonic 
days (E)11-18 along a caudo-rostral gradient, i.e. the more caudolaterally located 
nucleus basalis of meynert (NBM) arises prior to the more rostromedial diagonal 
bands of Broca (DBB) and the medial septum (MS) (Schwab et al., 1988) (Brady 
et al., 1989; Schambra et al., 1989).  Interestingly, some of the first studies 
identified that the progressive cholinergic degeneration in AD began in the 
nucleus basalis of Meynert (NBM) and followed along the same caudorostral 
gradient (Doucette and Ball, 1987).   
Before the proliferative MGE, LGE, POA areas arise, the early forebrain 
developmental pathway is initiated by prechordal mesoderm induction of ventral 
midline cells (rostral diencephalon) by cooperative signaling through contact-
mediated Sonic hedgehog (SHH) and diffusible bone morphogenetic protein 7 
(BMP7) gradients.  These morphogenic gradients establish the rostro-ventral 
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regionalization of the prospective forebrain around the 10-12 somite stage.  At 
this time, Nkx2.1 is expressed in progenitor cells of the MGE in the developing 
basal telencephalon and anti-BMP7 antibody blocks normal Nkx2.1 expression in 
the MGE (Dale et al., 1997).   
Nkx2.1 is a homeobox transcription factor whose expression is spatially 
restricted to the rostrobasal forebrain during development (Price et al., 1992) and 
Nkx2.1 repression in the developing dorsal telencephalon specifies ventral 
forebrain development (Sussel et al., 1999).  In Nkx2.1 mutant mice, Sussel et al,  
observed structural and cytochemical abnormalities in the  MGE induced by 
disrupted progenitor cell production and migration around E12.5.  Of major 
importance, by E18.5 the Nkx2.1 mutants displayed a complete loss of TrkA-
positive cells, an early cholinergic neuronal marker (Sobreviela et al., 1994) 
throughout the entire basal forebrain (Sussel et al., 1999).  From these studies it 
is apparent that normal Nkx2.1 expression within a highly regulated spatio-
temporal manner is essential for all cells originating and migrating through the 
MGE, including BFCNs.  In contrast to other MGE progenitor cells, BFCN Nkx2.1 
expression is maintained and can be observed in postmitotic BFCNs into 
adulthood (Wei et al., 2012).  Other functions ascribed to Nkx2.1 pertain to 
neuronal connectivity and migration of cells from the basal forebrain to the 
neocortex and striatum; however the role of Nkx2.1 in adult BFCNs has not been 
elucidated.   
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Whereas Nkx2.1 expression leads to regional specification of the MGE 
and initiates neuronal progenitor subtypes, LIM-homeobox (Lhx) genes are 
transcription factors which are expressed in parallel with Nkx2.1 in the 
developing basal forebrain (Wanaka et al., 1997).   Mice expressing mutant Lhx8 
(LIM-homeobox gene Lhx8/L3/Lhx7) also lacked cholinergic neurons in the 
telencephalic areas of the striatum, septum, and diagonal bands, but not in the 
nucleus accumbens or the magnocellular preoptic nucleus (Zhao et al., 2003).  
This demonstrates some heterogeneity in the cholinergic induction pathways and 
presents evidence for alternate mechanisms for cholinergic specification.  
Importantly, the loss of functional Lhx8 at E13.5 specifically blocked the 
formation of BFCNs in these areas without affecting other neuronal types.  When 
quantified, mutant Lhx8 resulted in ~75% reduction in cholinergic cell counts in 
the telencephalon and a significant loss of hippocampal cholinergic inputs.  
Subsequent studies by Mori confirmed that Lhx8 plays a pivotal role in the 
development and maintenance of BFCNs by targeting the expression of choline 
acetyltransferase (ChAT), vesicular acetylcholine transporter (VAChT) and the 
75kD/low affinity NGF receptor (p75/NTR), all of which are biochemical markers 
of the cholinergic phenotype (Mori et al., 2004).   
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BMP9 REGULATES THE BFCN PHENOTYPE 
 
Bone morphogenetic proteins are known to play a major role in body axis 
patterning during embryogenesis. BMP9 is abundantly expressed in the 
embryonic basal forebrain and spinal cord at E14 (Lopez-Coviella et al., 2000) 
and BMP9 induces Lhx8 expression (Bissonnette et al., 2011). The complete 
mechanism from Nkx2.1 to BMP9 induction of Lhx8 remains to be determined.  
The temporal expression of BMP9 and its receptor ALK1, have been shown to 
overlap with the critical period for BFCN differentiation.  E14 primary septal 
neurons transiently treated with BMP9 undergo dynamic morphological and 
molecular changes in vitro (Lopez-Coviella et al., 2000).  Instead of growing 
uniform monolayers, BMP9 treated septal cells organized into clusters and 
extended long TuJ1-positive projections.  These same neurons were also 
induced by BMP9 to express ChAT, VAChT and p75/NTR and displayed a 20-
fold increase in ACh production over PBS treated controls (Lopez-Coviella et al., 
2000).  Induction of the BFCN transcriptome and cholinergic phenotype by BMP9 
supports the idea that it acts as the differentiating factor responsible for the 
induction and maintenance of BFCNs (Lopez-Coviella et al., 2000; Lopez-
Coviella et al., 2005).  Moreover, intracerebroventricular (icv) infusion of BMP9 in 
mice with a unilateral septohippocampal lesion preserved the ChAT expression 
and prevented most of the cholinergic defects due to reduced hippocampal ACh 
levels.  BMP9 also caused increased expression of nerve growth factor (NGF) 
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and its receptors, p75/NTR and TrkA in the hippocampus ipsilateral to the lesion.  
BMP9 activates signaling pathways via serine-threonine kinase BMP receptors 
which phosphorylate Smad1/5/8 proteins.  BMP9 was identified to be 
developmentally regulated in parallel with various types of BMP receptors whose 
expression were also tightly regulated between E14 and perinatal time points in 
the mouse basal forebrain (Lopez-Coviella et al., 2006).  BmpR-Ib and Smad1 
proteins were highly expressed during E14-18 and BmpR-II protein levels 
increased around postnatal day 1 (P1) which were maintained into adulthood.  
Messenger RNA levels for another BMP receptor, Alk1 increased from E17 into 
adulthood and ALK1 was proposed as the maintenance receptor for BFCNs after 
differentiation.   In E14 cultured basal forebrain cells, Smad1/5 phosphorylation 
was quickly induced after BMP9 treatment, which also increased their 
translocation to the nucleus to complex with Smad4 for up to 1 hr.  This 
Smad1/5-Smad4 complex leads to activation of specific target genes (Massague 
and Wotton, 2000).  Once in the nucleus, gene targets of the TGF-β/BMP signal 
transduction require several coregulators for transcription initiation.  Smad-
interacting zinc finger protein, Sizn1, is a coregulator of BFCN differentiation at 
the transcription level.  Immunoprecipitation experiments showed that Sizn1 
directly interacts with Smad1 and recruits transcriptional machinery such as 
CBP/p300 to increase expression from the cholinergic gene locus coding for 
ChAT and VAChT.  Knockdown of Sizn1 in E13.5 primary septal cell cultures 
decreased ChAT and VAChT expression after BMP2 treatment (Cho et al., 
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2008).  Not only does this emphasize the ability of Sizn1 to activate the 
cholinergic gene locus but it also suggests overlapping signaling mechanisms 
between BMP2 and BMP9 to induce cholinergic phenotypic expression.  Indeed, 
BMP2 treatment of E14 septal cell cultures increased ACh production 15-fold, 
whereas BMP9 increased ACh production 20-fold as compared to PBS controls 
(Lopez-Coviella et al., 2002).  Given that BMP9 promotes Smad1/5 activation 
and nuclear translocation with Smad4, along with other undiscovered 
comodulators it is reasonable to hypothesize that Sizn1 may also mediate BMP9 
induced transcription from the cholinergic gene locus.   
These in vitro and in vivo experiments demonstrate that BMP signaling 
acts as a differentiation and maintenance pathway for the BFCN phenotype. 
Elucidation and confirmation of these developmental pathways has enabled the 
in vitro differentiation, maturation, transplantation and functional integration of 
BFCNs derived from pluripotent stem cells.  After stimulation with fibroblast 
growth factor 8 (FGF8) and SHH to produce neuronally committed progenitors 
competent to BMP9 treatment, human embryonic stem cells (hESCs) were 
differentiated into BFCNs in-vitro, grafted into ex-vivo mouse brain slices and 
then confirmed to be electrophysiologically active with voltage-clamp recordings 
(Bissonnette et al., 2011).  Exogenously applied BMP9 induced the BFCN 
phenotype and a dramatic increase in Lhx8 and Gbx1 mRNA transcripts were 
observed (Bissonnette et al.).  Overexpression of these two transcription factors 
was more efficient (94% vs. 85%) than BMP9 at producing BFCNs from hESCs.   
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 This is possibly due to BMP9 mediated regulatory feedback loops to modulate 
its own inductive signaling capacity in conjunction with Lhx8/Gbx1 transcriptional 
activation.  Furthermore, BMP9 treatment with Lhx8 knockdown by siRNA 
abrogated BFCN differentiation, providing further evidence for BMP9 
downstream signaling through Lhx8/Gbx1 to activate transcription of the 
cholinergic gene locus (Bissonnette et al., 2011).  These results confirm and 
strengthen the role of BMP9 mediated transcriptional activation as a sufficient 
event for BFCN development and advances the idea that BFCN generation from 
a patient’s own stem cells may hold therapeutic potential for diseases specifically 
affecting this neuronal subclass. 
Figure 1  BFCN differentiation from Nkx 2.1 expressing progenitors in the MGE and 
LGE at E10, to early BFCN  induction and specification at E14.  The morphogenic 
gradient induces transcription of BFCN cholinergic markers, ChAT, VAChT and the 
NGF/neurotrophin receptors at E18 which is maintained into adulthood. 
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Figure 2  Sagittal (A, top panel) and coronal (B, lower panel) views with basal 
forebrain nuclei labeled in white and projection targets in yellow and red arrows 
indicating BFCN projection paths. Modified from Mouse Brain Explorer 2, Allen 
Brain Institute. 
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BFCN PHENOTYPE 
 
In 1933, the neurophysiologist and Nobel Laureate, H.H. Dale proposed 
the term “cholinergic” for those neural pathways that utilize the neurotransmitter 
ACh.  These pathways are illustrated in the atlas presented in Figure 2.   The 
biochemical basis of the cholinergic system requires macromolecules to mediate 
ACh synthesis, release, synaptic transmission, degradation and choline 
reuptake.  In the cytoplasm, choline acetyltransferase (ChAT) forms ACh from 
the precursors, choline and acetyl-CoA (Bielarczyk and Szutowicz, 1989) (Jope 
and Jenden, 1980) which is essential for survival since transgenic ChAT 
knockout mice do not survive past postnatal day 1.  After ACh synthesis, BFCNs 
utilize vesicular acetylcholine transporter (VAChT) to sequester ACh into quanta 
or vesicles to be released from synapses and effect postsynaptic electrochemical 
signals.  Eliminating ACh release in the hippocampus by genetically reducing 
VAChT results in hyperactivity, impaired long-term potentiation and visuospatial 
memory (Martyn et al., 2012). 
ChAT and VAChT represent a unique “gene within a gene” organization 
on human chromosome10q11 establishing the cholinergic gene locus (CGL) 
(Eiden, 1998) illustrated in Figure 3.  VAChT is located within the first intron of 
the ChAT gene, allowing coordinate regulation of this gene locus whose 
organization is conserved through C. elegans, Drosophila and H.sapiens.  
Coordinate regulation does not necessarily imply coordinate expression.  The 
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effects of both CNTF/LIF and retinoic acid receptor-α (RAR-α) stimulation by all-
trans-retinoic acid led to proportional increases in ChAT and VAChT mRNA 
expression, whereas a 2- and 4-fold increase,respectively was observed in a 
septal cell line after cyclic-AMP treatment (Berse and Blusztajn, 1995).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3  The cholinergic gene locus (CGL) codes for ChAT (its central and 
peripheral variants) as well as VAChT from chromosome 10.  The CGL consists 
of 3 non-coding (R, N, M) and 15-16 coding exons depending on the species.  
(*) represent transcriptional start sites for the 5 alternative ChAT variants.  The 
intronless VAChT gene is located within the first intron, between the first two 
non-coding exons of the full-length ChAT reading frame.  
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Differential expression patterns from a common locus could be accomplished by 
multiple response elements (RE) in the cholinergic gene locus such as a BMP-
RE, cAMP-RE, repressor complexes or additional interactions that regulate 
transcription through epigenetic modification.  REST4, a transcriptional activator, 
can de-repress the gene silencing action of the REST/CoREST complex and 
activate the cholinergic gene locus in a protein kinase A (PKA) dependent 
manner (Hersh and Shimojo, 2003).  This may explain the coordinate regulation, 
but differential expression in ChAT and VAChT mRNA when the septal cells were 
treated with PKA activating cAMP (Berse and Blusztajn, 1995).  Epigenetic 
modifications may promote regulation of expression from the cholinergic gene 
locus as histone deacetylase 9 (HDAC9), a class IIa enzyme that removes an 
acetyl group from the histone N-terminal tail and represses the ChAT promoter in 
neuronal cultures (Aizawa et al., 2012).  Multiple layers of complex regulatory 
mechanisms govern ChAT and VAChT expression from the cholinergic gene 
locus, to establish the biochemical basis of all properly functioning cholinergic 
neurons, however the exact mechanisms for the differential expression patterns 
of ChAT and VAChT from a common locus remains elusive.   
 Postsynaptic molecules such as ionotropic, nicotinic acetylcholine 
receptors (nAChR), metabotropic muscarinic acetylcholine receptors (mAChR), 
the hydrolytic enzyme, acetylcholinesterase (AChE) control the electrochemical 
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neurotransmission signals provoked by ACh release.  Each of these factors is a 
salient feature of acetylcholine neurotransmission.     
VAChT, a twelve membrane domain transporter protein, is localized in the 
nerve terminals where it transports ACh into synaptic vesicles.  Presynaptic 
excitation of a cholinergic neuron induces calcium-dependent exocytosis of ACh 
in the synapse (Li et al., 1995a). 
Exocytosis of ACh is mediated by a series of highly-regulated docking, 
synaptic membrane-vesicular fusion and lastly, vesicular recycling mechanisms 
(Sudhof, 1995).  Postsynaptic nAChR and mAChRs, as well as mAChR 
autoreceptors located presynaptically can bind ACh (Blusztajn and Berse, 2000) 
to initiate temporally-defined patterns of intracellular signaling and gene 
expression pathways.  AChE, a carboxylesterase capable of hydrolyzing 36,000 
molecules of ACh into free acetate and choline per second, effectively terminates 
the neurotransmitter signal.  The choline transporter 1 (ChT1) is responsible for 
the presynaptic, sodium-dependent, high-affinity choline reuptake which recycles 
choline for another round of ChAT catalyzed ACh synthesis and VAChT 
sequestration (Eiden, 1998; Okuda et al., 2000).  
These macromolecules modulate the cholinergic effects to optimize neural 
circuits throughout the entire brain.  ACh is important for mechanisms of synaptic 
plasticity, which is activity-dependent strengthening or weakening of synapses, 
thought to be responsible for learning acquisition, memory storage and retrieval, 
and long term neural circuit maintenance (Picciotto et al., 2012).  
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Both choline and acetyl-CoA are essential for cellular metabolic pathways 
and the production of acetylcholine in BFCNs.  Age induced metabolic stress and 
this double utilization of acetyl-CoA and choline in cholinergic neurons may 
increase BFCN susceptibility to dysfunction and degeneration leading to 
cognitive and memory impairments (Perry et al., 1980; Wurtman, 1992) 
(Szutowicz et al., 1996).  
As choline can be metabolized from phosphatidylcholine, a major 
component of the plasma membrane, diseases that result in cholinergic 
dysfunction may destabilize the plasma membrane and cytoskeletal dynamics to 
cause morphological changes in BFCNs.  Our initial observations in 6- and 24-
month old mice indeed revealed morphological changes with age in BFCNs.  We 
observed retracted arborizations as cell bodies appeared more rounded and 
smaller in size, as illustrated in Figure 4.  With AD-like amyloidosis, BFCNs in AD 
model mice appear smaller and have tortuous, stunted projections as illustrated 
in Figure 5 and representative of the cholinergic defect the APP/CHGFP mice.  
These morphological changes in wild type (WT/CHGFP) mice with age and in AD 
model (APP/CHGFP) mice are in line with previous reports and highlights the 
susceptibility of BFCNs to morphological changes with aging and AD.   
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Figure 4 Age-induced morphological changes of BFCNs in the 
MSN/VDB of 6 months (top) and 24 months old (bottom) WT/CHGFP 
mice (20x objective).  Note: Aged BFCNs have shorter processes 
and have taken on a smaller, more spherical shape in contrast to the 
ellipsoid somas and long projections evident in the 6-month old 
BFCNs. 
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Figure 5  Reduced BFCN cell size and stunted axonal projections in 
the MSN of the APP/CHGFP AD mouse model expressing eGFP from 
the ChAT promoter (40x, objective lens). 
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NERVE GROWTH FACTOR AND ITS RECEPTORS 
 
Discovery of nerve growth factor (NGF), the first growth factor, by Rita Levi-
Montalcini in the 1950s transformed modern neuroscience and earned Dr. Levi-
Montalcini the 1986 Nobel Prize.  Initially, NGF was shown to regulate cell 
growth, differentiation and survival of noradrenergic neurons.  Later it was 
learned that NGF’s mechanism of action influenced multiple neuronal cell 
populations in the CNS and PNS (Aloe, 2004).  High concentrations of NGF in 
the terminal cholinergic targets of the cerebral cortex and hippocampus 
implicated an NGF-cholinergic association (Johnson et al., 1987).  Co-expression 
of the NGF receptors, TrkA and p75/NTR with ChAT is a characteristic only 
observed in BFCNs and demonstrates a reliance on NGF signaling in the basal 
forebrain (Sobreviela et al., 1994).   
NGF and its receptors are now known to be important for the development and 
maintenance of BFCNs and NGF has been shown by multiple groups to increase 
ACh levels (Berse et al., 1999; Auld et al., 2001), ChAT (Gnahn et al., 1983) , 
VAChT (Berse et al., 1999), and TrkA expression (Li et al., 1995b).  NGF is also 
induced by BMP9 in dissociated E14 primary septal cell cultures (Schnitzler et 
al., 2010).  These data suggest that both NGF and BMP9 have overlapping 
functions to support BFCN development, survival and phenotypic maintenance 
throughout neurodevelopment into adulthood.  In aged rats (26-30 month old), 
impairments to BFCN NGF retrograde transport resulted in a 60% reduction in 
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cholinergic cell size and a 43% decline in TrkA mRNA leading the authors to 
propose this as a mechanism for cholinergic hypofunction and degeneration in 
aging and AD (Cooper et al., 1994).  
 Furthermore, triple colocalization of p75/NTR and TrkA NGF receptors 
with ChAT is restricted to the cholinergic neurons of the basal forebrain and their 
respective projection sites in the CNS (Sobreviela et al., 1994) making these 
molecules markers of the BFCN network. Sobreviela (Sobreviela et al., 1994) 
performed an extensive quantitative analysis of TrkA and p75/NTR distributions 
in the CNS and found virtually all (>95%) TrkA+ neurons in the MS/DBB were 
positive for p75/NTR and ChAT with slightly less colocalization of all three BFCN 
markers in the NBM (~85%).   
TrkA, a type-I receptor tyrosine kinase, has high-affinity for the processed, 
mature form of NGF and initiates cell signaling cascades, receptor mediated 
endocytosis and retrograde transport of NGF to the BFCN soma for survival and 
maturation of BFCNs and maintenance of their target innervation (Fagan et al., 
1997; Moises et al., 2007; Niewiadomska et al., 2011).  Conversely, p75/NTR is 
a promiscuous neurotrophin receptor that has a lower affinity for NGF and 
prefers to bind immature proNGF when acting unilaterally (Sofroniew et al., 
2001).  More specifically, loss of NGF signaling in TrkAnull mice produces 
significantly smaller and fewer BFCNs (Fagan et al., 1997); whereas deletion of 
p75/NTR in mice results in increased BFCN counts and cholinergic fiber 
hyperinnervation of hippocampal targets (Yeo et al., 1997).   At baseline, 
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p75/NTR is expressed in a 10:1 ratio with TrkA and the vulnerability of BFCNs to 
changes in TrkA/NGF signaling may mediate neuronal shrinkage, dysfunction 
 
 
 
   
    
 
 
 
 
Figure 6  Co-expression of transgenic ChAT-eGFP (green) and endogenous 
p75/NTR (red) in the MSN/VDB provides a positive control validating eGFP 
expression in ChAT/p75-positive BFCNs.  Note: Compare the anatomical 
features of MS/VDB in this figure to the atlas in Figure 2B. 
 22 
or death, as in aging and AD when TrkA:p75/NTR expression ratios are altered 
(Chao and Hempstead, 1995).  TrkA downregulation coupled with impaired 
retrograde axonal transport in the basal forebrain is one of the early findings in 
AD and correlates significantly with lower cognitive performance (Mufson et al., 
1996). 
p75/NTR has demonstrated pro-survival capabilities by increasing the 
specificity of TrkA, as well as TrkB and TrkC neurotrophin receptors for their 
respective growth factors i.e, NGF, BDNF and NT-3 respectively (Kaplan and 
Miller, 1997).  In the absence of ligand, co-immunoprecipitation experiments 
have demonstrated binding between the p75/NTR and TrkA (Huber and Chao, 
1995) which required both the intact extracellular and intracellular domains of 
both proteins (Bibel et al., 1999).  The p75/NTR-TrkA co- receptor increased 
NGF responsiveness and neuronal survivability (Chao and Hempstead, 1995).  
   Much research regarding BFCN phenotypic changes and receptor 
expression levels during aging and AD has been carried out, however these 
studies have not been entirely consistent.  In particular, studies on the role of 
p75/NTR in AD have been controversial with research showing both 
neuroprotective and neurotoxic effects.  p75/NTR has a highly conserved death 
domain which in certain contexts are known to induce apoptosis.  However, in 
cholinergic neurons p75/NTR downregulates cholinergic markers but does not 
induce apparent cholinergic cell death (Barrett, 2000).  In mice with p75/NTR 
functional deletion mutation, Greferath (Greferath et al., 2012) found the number 
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and size of ChAT expressing BFCNs increased but the number of p75/NTR-
positive neurons in the basal forebrain was unchanged suggesting a 
nonapoptotic, antineurotrophic role for p75/NTR.   
Earlier human studies observed a 38% and 43% reductions in p75/NTR 
expressing neurons in the basal forebrains of humans with mild cognitive 
impairment and mild AD, respectively (Mufson et al., 2002).  The latter found that 
the reductions of p75/NTR were significantly correlated with cognitive 
impairment, as determined by the Mini-Mental State Exam and the Global 
Cognitive Test.   
These conflicting reports are not surprising, given the complexities 
surrounding the physiological role of p75/NTR receptor itself.  proNGF-p75/NTR 
can cause caspase activation and lead to apoptosis.  Not only can p75/NTR 
undergo proteolytic cleavage by the Beta-Amyloid Converting Enzyme (BACE) 
(Zampieri et al., 2005), but it can also promote cleavage of APP to generate 
insoluble Aβ (Costantini et al., 2005).  p75/NTR also binds to Aβ in primary 
hippocampal cultures (Kuner et al., 1998) and intrahippocampal Aβ injections 
were dependent on p75/NTR expression in vivo to produce neurotoxic effects 
(Sotthibundhu et al., 2008).   
In contrast, there are multiple lines of evidence suggesting that p75/NTR 
may mediate anti-Aβ aggregation and pro-survival functions. BACE cleavage of 
the p75/NTR extracellular domain (ECD) can confer protection from neurotoxic 
amyloid oligomers.  Zhang (Zhang et al., 2003) found a dose-dependent 
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upregulation of p75/NTR in primary human neurons exposed to Aβ1-40 and Aβ1-42.  
This correlated with increased neuronal survivability in a PI3K-Akt dependent 
mechanism.  Transfecting the same cells with a plasmid encoding anti-sense-
p75/NTR effectively reduced p75/NTR levels and sensitized these neurons to 
Aβ1-42 cytotoxicity (Zhang et al., 2003).  Another study by Wang et al, showed 
that p75/NTR increased Aβ production and deposition in the APPswe/PS1dE9 
mouse model of AD, but inhibited Aβ aggregation with its extracellular domain 
(ECD).  Injection of the p75/NTR ECD into the hippocampus of p75/NTRnull-
APPswe/PS1dE9 mice significantly reduced the area fraction of Aβ plaques in 
these mice (Wang et al., 2011).  Wang et al, also found elevated insoluble Aβ in 
sera and less Aβ in the brains of p75/NTR+/+ mice, as compared to p75/NTRnull-
APPswe/PS1dE9 mice, suggesting that p75/NTR may prevent Aβ aggregation 
and increase Aβ clearance.   
p75/NTR expression is consistently increased by BMP9 in-vitro and in-vivo 
(Lopez-Coviella et al., 2000; Lopez-Coviella et al., 2005; Schnitzler et al., 2008b).  
Since BMP9 is important for BFCN development, maturation and maintenance, it 
would be worthwhile to determine whether BMP9 modulates the enzymatic 
proteolysis of p75/NTR ECD toward the more advantageous, neuroprotective 
pathway during AD pathology. 
 
 
 
 
 
 25 
   
 
 
 
 
 
 
 
 
 
 
Figure 7  Colocalization of transgenic ChAT-eGFP and p75/NTR expression 
in the VDB. Costes Colocalization Coefficient (M1): 0.999; Costes 
Colocalization Coefficient (M2): 0.957.  These colocalization coefficients 
calculated by Volocity software for the representative image support the 
findings of (Sobreviela et al., 1994). Note the morphology and the 
overlapping densities of the p75/NTR and ChAT fiber networks. 
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ALZHEIMER’S DISEASE  
 
AD is a complex, neurodegenerative disease that robs humans of their 
most valuable, personal possession: their mind.  AD is diagnosed by the 
presence of two histopathologic hallmarks: Aβ plaques and neurofibrillary tau 
tangles.  Major brain regions affected by AD are the neocortex, the medial 
temporal lobe and adjacent limbic structures including the hippocampus and 
amygdala, as well as the cerebellum.  Atrophy and dysfunction in these regions 
which are responsible for learning, attention, memory, insight, judgment, 
orientation, emotion and other higher executive abilities lead to global loss of 
cognitive ability.  Included in this global cognitive impairment are memory loss, 
dementia, psychosis, depression, aggression/agitation and other behavioral 
detriments. 
AD is a disorder with a strong genetic component and is divided into 
familial and sporadic forms..  Approximately 25% of AD is the familial form and 
the rest fall under sporadic.  Late-onset AD (LOAD) is the most common variety 
of sporadic AD and typically affects those 65 years and older.  Sporadic AD is 
thought to arise due to age-induced exposures and accumulation of 
environmental risk factors, however very little is known about the etiology of 
sporadic AD (Bird, 1993).  Recently, genome wide association studies have 
found a strong genetic component leading to increased risk of early-onset, 
familial AD as well as late-onset (sporadic AD) (Guerreiro et al., 2013).   
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The familial form of AD is much less common and is associated with early 
onset AD (EOAD) in people less than 65 years old.  Familial AD displays an 
autosomal dominant pattern of inheritance.  The genetic variants in the genes 
coding for APP, PSEN1 and PSEN2 are deterministically associated with early-
onset AD.  Late onset-AD is associated with specific genetic variants in the 
genes coding for TREM2, MTHFD1L, BCHE, CR1, CLU, BIN1, PICALM, MS4A, 
CD2AP, EPHA1, ABCA7 and CD33.   However, aging and inheritance of the 
apolipoprotein ApoE4 allele have the largest effect of AD risk (Naj et al., 2011; 
Guerreiro et al., 2013).   
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AD GENETIC 
VARIANT 
 
TYPE OF AD DISEASE IMPLICATION or 
GENE FUNCTION 
APP, PSEN1/PSEN2 Deterministic, Early-onset 
AD 
Increased production of toxic Aβ 
intermediates and plaque formation  
APOE4 
 
Late-onset AD Defective lipid and amyloid 
clearance  
TREM2 
 
Late-onset AD Defective microglial phagocytosis  
EPHA1 
 
Late-onset AD Axon guidance and ADAM10 
metalloprotease substrate 
recognition (OMIM: 179610) 
CD2AP Late-onset AD Vesicle formation and cytoskeletal 
polarization 
(OMIM: 604421) 
CR1 Late-onset AD Complement receptor and activator 
of innate immune response (OMIM: 
120620) 
CLU Late-onset AD Clearance of cellular debris and 
apoptosis (OMIM: 185430)  
BIN1 Late-onset AD Tumor suppressor that interacts 
with phospholipases  
MTHFD1L Late-onset AD Conversion of methionine from 
homocysteine  
BCHE Potential association with 
Early and Late-onset AD 
Hydrolysis of ACh and correlates to 
plaque burden.  
TABLE 1 Selected genetic variants identified as risk factors for early-onset 
and late onset AD.  Gene function listed instead of pathologic contribution 
since most genetic variants are only associated with AD risk and have not 
yet been causally linked to AD pathophysiology.  
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Diagnosing Alzheimer’s disease has been challenging because the cognitive 
dysfunction, memory loss and behavioral changes occur many years after the 
onset of disease progression  (Niedowicz et al., 2012).  Until recently, a 
confirmatory diagnosis of AD was only available after postmortem autopsy 
analysis for Aβ plaques and neurofibrillary tangles.  Advances in PET imaging 
and biomarker discovery may enable early diagnosis and the initiation of 
preventative or symptomatic treatments of for humans with preclinical AD.   
 
 
 
 
 
 
 
 
Figure 8  Positron Emission Tomography (PET) scan images of a cognitively 
normal brain compared to an AD brain.  Aβ plaques are radiolabeled with 
Pittsburgh compound B (PiB) which is now used to help diagnose AD before 
symptoms are evident.  Higher PiB concentration (red and yellow regions) 
indicates increased presence of Aβ plaques.  Image from Alzheimer’s Disease 
Education and Referral center, National institute of Aging. 
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Research into the genetic components of AD has allowed the generation 
of transgenic mice to study certain parameters of the disease pathophysiology in- 
vivo.  Although not a complete recapitulation of human AD pathology, these mice 
can be engineered as classical knockouts, transgenics or knock-ins to test 
certain AD genes and gene-gene interactions.  Most AD mouse models focus on 
APP and Aβ plaque formation, however double-, triple-, on up to 5x- transgenic 
mice have been produced to study narrow or broad aspects of AD 
pathophysiology.  These mice exhibit reactive gliosis and inflammation, 
dystrophic neurites and cognitive deficits which are also observed in human AD, 
but the mice lack significant brain atrophy (Mineur et al., 2005; Oakley et al., 
2006).  Our studies involve the APPswe/PS1dE9 mouse model of AD engineered 
to express mutated human forms of APP and PSEN1 which are known to be 
deterministic of AD in humans (see Materials and Methods for more info on 
APPswe/PS1dE9 mice).  Previous studies have found these mice display 
progressive amyloidosis with a significant cholinergic deficit (Figures 5, 10, 11 
and 15) and cognitive impairments (Savonenko et al., 2005) (Gimbel et al., 
2010).  
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Aβ HYPOTHESIS OF AD  
 
AD is a progressive disease characterized by memory loss and cognitive 
impairment exacerbated by Aβ-induced synaptic failure (Selkoe, 2002).  There is 
now a large body of evidence implicating Aβ as the molecular pathogenic culprit 
of AD, which has culminated into the Aβ hypothesis.  Aβ monomers, oligomers, 
fibrils and plaques generated from insoluble fragments of the amyloid precursor 
protein (APP) cleavage have been extensively investigated and it is widely 
accepted that Aβ deposition disrupts molecular, cellular and neuronal network 
dynamics. The Aβ hypothesis provides a mechanistic explanation for progressive 
AD and according to Walsh (Walsh and Selkoe, 2004) is supported by the 
following observations:  1) progressively increased Aβ peptide deposition around 
neuritic and dystrophic neurites in the cortex and hippocampus, 2) synthetic Aβ 
peptides display in vitro and in vivo toxicity, 3) inherited APP mutations results in 
higher production of amyloidogenic Aβ , 4) transgenic animals with APP and 
presenilin PSEN1/PSEN2 mutations generate greater levels of the more toxic 
Aβ42 peptide, resulting in more severe, rapid onset AD-like pathology, and 5) 
strong correlations have been identified between Aβ oligomers, cognitive deficits 
and synaptic retraction.   
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Aβ TARGETED THERAPEUTICS 
 
The Aβ-hypothesis has opened the possibility of immunotherapies for 
inhibiting amyloidosis in the brains of AD patients.  This was first attempted in 
humans in a clinical trial of intravenously infused bapineuzumab which reduced 
Aβ burden and tau aggregation, but it failed to demonstrate any improvements in 
cognition or activities of daily living (Lobello et al., 2012).  
It is difficult to interpret these results due to the late initiation of treatment 
in the disease process as plaque accumulation and synaptic degeneration is 
known to occur decades before symptoms of cognitive dysfunction appear.  To 
address this issue, the very first AD prevention trial was approved by the NIH and 
will systematically test Genentech’s anti-Aβ antibody crenezumab in a pre-
symptomatic Columbian cohort (n=300) harboring the PSEN1 (E280A) mutation.   
A smaller group of pre-symptomatic American participants with other presenilin 
mutations from the DIAN cohort will also receive crenezumab (Selkoe, 2012).  
The outcome of this preventative study will likely represent the largest and most 
authoritative challenge to the Aβ-hypothesis. 
One reason Aβ has garnered so much attention is because the molecular 
underpinnings of APP catabolism and generation of neurotoxic Aβ is the most 
understood process in AD pathophysiology.  In addition, understanding the 
pathogenic pathways and molecular regulation of Aβ generation from APP 
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provides multiple targets for prevention and/or treatment.  APP is sequentially 
cleaved by BACE and gamma-secretase to generate Aβ40 and Aβ42 fragments.  
Pharmacological approaches developed by Eli Lilly, using the gamma-secretase 
inhibitor semagacestat (LY450139) to prevent Aβ generation showed significant 
dose-dependent reductions of Aβ40 in human CNS over 12 hours (Bateman et al., 
2009), however Phase III clinical trials were abruptly ended as results indicated 
worse cognitive performance compared to placebo.  Further complications 
included gastrointestinal irritability and increased risks of skin cancer due to 
interference of signaling by Notch – a known substrate for gamma-secretase 
(Imbimbo and Giardina, 2011).   Elan Pharmaceuticals has since developed and 
tested ELN475516, a gamma secretase inhibitor that specifically inhibits 
cleavage of APP and reduces Aβ40 without interfering with Notch signaling in 
mice (Basi et al., 2010).  The safety or effectiveness of ELN475516 remains to 
be tested in humans.    
Inhibiting Aβ generation is more appealing than blocking fibrillary plaque 
formation because the smaller Aβ oligomers are thought to be more toxic to 
synapses (Lue et al., 1999) and Aβ oligomers are a better determinant of 
neurodegeneration and cognitive decline than Aβ plaques (McLean et al., 1999).  
By decreasing the number of plaques without increasing the clearance rate of Aβ 
oligomers, a potential therapy may increase the number of free oligomers (or 
dimers and trimers).  This might actually induce more harm than good since Aβ 
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oligomers are more hydrophobic and are known to interfere with CNS physiology 
at multiple levels. 
Aβ DISRUPTS MULTIPLE NETWORKS IN AD 
Olzscha et al. (Olzscha et al., 2011) have proposed that amyloid-like 
aggregates induce a “fatal network collapse” by affecting key cellular processes 
such as chromatin remodeling, transcription, vesicular transport, signaling and 
cytoskeletal dynamics.  In addition to synaptic retraction and degeneration, 
multiple groups have shown that Aβ interferes with AMPA-R, NMDA-R, nACh, 
mACh and mGlu5 receptors at synapses.  This would disrupt intracellular 
functions as well as local circuit connections and ultimately larger neuronal 
networks (Palop and Mucke, 2010).  As mentioned earlier, Aβ oligomers have 
been shown to bind p75/NTR, nAChRs, mAChRs and PrPc all of which are 
expressed pre- or post-synaptically as a part of the cholinergic network.  This 
suggests that the Aβ-hypothesis and cholinergic hypothesis of AD may not be 
mutually exclusive.   
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Additionally, Aβ has been found to bind, sequester and negatively affect  
intracellular transport by inducing tau hyperphosphorylation via α7-nAChRs, 
mitochondrial release of cytochrome C to activate apoptotic cascades, and 
initiating the stress-induced unfolded protein response in the ER.  Aβ possesses 
nanomolar affinity for the PrPc protein and this interaction was essential to 
mediate Aβ-induced toxicity and cognitive impairment (Lauren et al., 2009).  
However, less specific interactions with other proteins may be propagated 
through the disordered, unstructured domains allowing Aβ to evolve an aberrant 
Figure 9 Aβ disrupts multiple functional networks at the molecular, 
synaptic, local circuits and neuronal network levels. 
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interactome interfering with essential function and inducing toxicity (Bolognesi et 
al., 2010).  Aβ contains a hydrophilic, extracellular domain and a hydrophobic, 
intramembrane domain which allows Aβ monomers to act as nucleating centers 
to create expanded oligomers.   These hydrophilic-hydrophobic regions establish 
structural disorder within Aβ to induce aggregation of individual monomers into β-
sheet rich oligomers, fibrils and plaques.  These pathogenic Aβ units then 
interact and sequester numerous proteins with essential functions disrupting a 
host of physiological functions (Olzscha et al., 2011).  This amyloid induced fatal 
network collapse in molecular and cellular networks can be extrapolated to larger 
neuronal networks that require interconnected brain regions for appropriate 
social, emotional and behavioral integration.  As these interconnections suffer 
synaptic failure and neurodegeneration, network efficiencies in the brain become 
compromised then cognitive and behavioral impairments ensue. 
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TAU HYPOTHESIS OF AD  
 
Tau (also known as, MAPT) is a member of microtubule associated 
protein (MAP) family.  Tau provides structural integrity and stability to 
microtubules.  In the CNS, microtubules influence neuronal morphology, dendritic 
scaffolding and intracellular transport of nutrients, neurotransmitters and 
organelles such as mitochondria and rough endoplasmic reticulum.  These 
processes are essential for cytoskeletal maintenance, synaptic plasticity and cell 
viability (Savelieff et al., 2013).  Various mechanisms resulting in tau 
hyperphosphorylation induces its dissociation from microtubules yielding “seeds” 
of intracellular tau monomers to form oligomers, granules and neurofibrillary 
tangles (NFTs) (Takashima, 2010).  Phosphorylated tau is also resistant to both 
proteolytic cleavage by CAPN2 a calcium-activated neutral protease, as well as 
polyubiquitin mediated proteosomal degradation (Iqbal et al., 2009).  These 
conditions lead to increased intracellular concentrations of the pathologic tau 
intermediates which form the NFTs.    
NFTs can be observed in the frontal and temporal lobes of the neocortex, 
the entorhinal cortex as well as limbic structures of the AD brain and are 
correlative of synaptic and neuronal loss (Takashima, 2010) (Braak and Braak, 
1991).  Evidence for the tau hypothesis of AD include:  1) NFTs, in the absence 
of amyloid plaques, are found in brains afflicted with other dementia-related 
pathologies (Ward et al., 2012),  2) Neurodegeneration correlates with phospho-
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tau/NFT levels but not amyloid plaques (Iqbal et al., 2009) (de Souza et al., 
2012),  3) Normal, aged individuals may contain Aβ plaque burdens as high as 
AD patients, but lack tau-positive dystrophic neurites and neuritic plaques 
(Dickson et al., 1992), 4) overexpression of the P301S human tau mutation in 
transgenic mice induces cortical, hippocampal and amydalar NFT formation, 
inflammatory gliosis and neurodegeneration (Yoshiyama et al., 2007).   
The extent of NFTs in the brain strongly correlate with neurodegeneration 
and cognitive impairment in AD (Braak and Braak, 1991).  Using NFT 
immunostaining, Braak and Braak, identified six different stages of AD pathology 
as defined by the amount of NFT involvement in postmortem human brain 
samples.  Braak and Braak (BB) stages I/II include NFTs confined to the 
transentorhinal area, BB stages III/IV include NFTs in the hippocampus and other 
limbic regions and BB stages V/VI refer to extensive NFTs throughout neocortical 
regions.    
Tau can be phosphorylated on 38 serine/threonine residues by multiple 
kinases including glycogen synthase kinase-3 (GSK-3), cyclin-dependent kinase-
5 (cdk5), protein kinase A (PKA), the extracellular regulated kinases (ERK1/2), 
stress-activated protein kinases (SAPKs) casein kinase 1 (CK-1) and FYN-
kinase.  Interestingly, a single nucleotide polymorphism (rs7768046) in the FYN-
kinase and (rs913275) in the PPP2R4 phosphatase are associated with 
increased total-tau and phosphorylated tau in cerebrospinal fluid from AD 
patients (Bekris et al., 2012).  
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Whereas multiple kinases facilitate tau hyperphosphorylation, a relatively 
few number of phosphoprotein phosphatases are able to balance this pathologic 
mechanism.  Only PP-1, PP-2A and PP-2B have been shown to dephosphorylate 
and inhibit tau’s self-assembly to preserve microtubule stability (Wang et al., 
1996).  Significantly decreased phosphatase activity has been measured in AD 
brains, suggestive of a dephosphorylation defect that contributes to the 
phosphor-tau mediated pathophysiology of AD (Gong et al., 1993; Guadagna et 
al., 2012).  These studies may lead to tau-specific phosphatase activators or 
kinase inhibitors to reduce tau hyperphosphorylation and preserve the neuronal 
cytoskeleton, intracellular transport or possibly even cognitive function. 
 
CHOLINERGIC HYPOTHESIS OF AD 
 
The cholinergic hypothesis of AD proposed by Bartus (Bartus et al., 1982) 
is supported by a vast body of research pertaining to: 1) alterations in choline 
uptake, the rate-limiting step for ACh synthesis (Slotkin et al., 1990), 2) reduced 
ChAT activity and ACh release, 3) reduced (α7)-nAChR expression (Hernandez 
et al., 2010), 4) dysfunctional or reduced M1/M3-mAChR expression (Terry and 
Buccafusco, 2003), and 5) impaired cholinergic axonal transport of NGF (Mufson 
et al., 1996).  Dystrophic cholinergic neurites, neuritic plaques and reduced 
hippocampal and cortical cholinergic innervation as well as reduced BFCN 
counts and synaptic degeneration have all been observed in human and 
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transgenic mouse models of AD (Mufson et al., 2003; Perez et al., 2007).  One of 
the earliest observed features discovered in postmortem AD brains is the 
pronounced cholinergic degeneration which is correlated to severity of memory 
loss and cognitive decline.  After Davies (Davies and Maloney, 1976) reported a 
selective loss of cholinergic neurons in AD patients, it was postulated that AD 
may be a selective neurotransmitter disease affecting acetylcholine signaling.   
Subsequent losses of cholinoceptive pyramidal neurons and even greater 
synaptic degeneration in the cortex as measured by synaptophysin staining are 
the strongest correlates of dementia and memory loss (Terry et al., 1991; Francis 
et al., 1999).  
Further support for the cholinergic hypothesis comes from studies 
demonstrating various cognitive dysfunction and learning impairments in mice, 
rats, monkeys and humans with basal forebrain lesions and pharmacological 
cholinergic blockade (Terry and Buccafusco, 2003).  Blocking cholinergic 
signaling with the mAChR antagonists, scopolamine, atropine or glycopyrrolate 
produce amnestic effects with age-related sensitivity whereas memory 
improvements have been observed with specific nAChR and mAChR agonists 
(Ray et al., 1992; Terry and Buccafusco, 2003). 
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Figure 10  Laser scanning confocal micrograph of Aβ42 immunostaining (red) 
in the hippocampus (left) and cerebral cortex (right) in APP/CHGFP mice.  
Note: dystrophic, tortuous neurites adjacent to the plaques and the weak, 
punctate network of cholinergic fibers (green), (40x objective lens). 
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CHOLINERGIC THERAPEUTICS 
 
The only approved therapeutic drugs for AD block AChE to inhibit ACh 
hydrolysis thereby potentiating ACh neurotransmission at the synapse.  The first 
generation AChE inhibitor, tacrine showed significant improvement in cognition 
and quality of life as measured by Alzheimer’s Disease Assessment Scale-
cognitive subscale (ADAS-cog) scores and Clinician Interview Based Impression 
of Change plus caregiver input (CIBIC+) tests.  However, given that ACh has 
widespread modulatory effects in the gastrointestinal and cardiovascular 
systems, multiple side effects involving gastrointestinal discomfort, nausea, 
vomiting, cardiovascular complications and hepatotoxicity reduced long-term 
Figure 11  Abnormal cholinergic morphologies in the vertical limb of the 
diagonal band (A), striatum (B) and cerebral cortex (C) of 8 month old 
APP/CHGFP mice, (20x objective lens). 
C B A 
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patient compliance and the effectiveness of tacrine (Terry and Buccafusco, 
2003).  
 Second generation AChE inhibitors such as donepezil have reduced side 
effects while demonstrating similar improvements in cognitive function as well as 
delaying reductions in activities of daily living (ADLs) by up to a year (Rogers et 
al., 1998).  Early to mild AD patients receiving donepezil demonstrated improved 
quality of life, reduced amount of direct supervision and delayed 
institutionalization.  However not every AD patient responded equally to 
donepezil treatment and none of the AChE inhibitors improve cognitive 
performance to normal levels (Mesulam, 2004).   
The cholinergic hypothesis merely explains the insidious loss of attention 
and working memory during aging and AD (Schliebs and Arendt, 2011). 
Potentiating cholinergic neurotransmission to improve cognition simply treats the 
symptoms of AD and not the underlying cause, making it difficult, if not 
impossible to pharmacologically counterbalance the cognitive assault of the 
causative agent with AChE inhibitors or AChR agonists.  The causative agent for 
AD has remained elusive, however various cellular and molecular biological 
approaches have yielded tremendous gains in the understanding of AD 
pathophysiology.   Multiple studies indicate that BFCN dysfunction and/or 
degeneration contributes to the memory deficits in advanced aging and AD 
(Mufson et al., 2008; Grothe et al., 2012; Haense et al., 2012).   
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Therefore, interventions that inhibit Aβ-deposition or tau-phosphorylation 
while protecting BFCN viability may preserve ACh neurotransmission thus 
preserving memory function and improving cognition.  
 
MATERIALS AND METHODS 
Transgenic Mice 
The following strains were used:  
1) AD model mice B6C3-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax and  
2) transgenic mice expressing the enhanced green fluorescent protein in 
cholinergic cells: B6.Cg-Tg(RP23-268L19-EGFP)2Mik/J. 
Briefly, the AD model mice express two separate transgenes that inserted into a 
single locus, both under control of the prion promoter.  The first transgene is the 
murine APP protein harboring the human Aβ sequence with Swedish mutations, 
K595N/M596L (APPswe), associated with the familial form of AD. The second 
transgenic insert harbors the human presenilin 1 (PS1) protein with a deleted 
ninth axon (PS1dE9), which was discovered in individuals with early-onset 
familial AD.  In order to study the cholinergic phenotypic changes during AD-like 
progression in the APPswe/PS1dE9 model, these mice were crossed with 
transgenic C57BL/6J mice expressing GFP under the control of the Chat 
promoter.  The triple transgenic offspring of APPswe/PS1dE9 (APP.PS1) x 
CHAT-GFP (CHGFP) will be referred to throughout the paper as APP/CHGFP.  
All mice were kept on a 12 hour light-dark cycle and given food and water ad 
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libitum.  This study used 6- and 8-month-old AD/CHGFP and WT/CHGFP mice 
for the microarray study and PrPc immunofluorescence, respectively.  Genotypes 
were confirmed with PCR primers specific for human APP.  APP/PS1null 
homozygous ChAT-GFP+/+ transgenic mice expressing GFP from the ChAT 
promoter, were used as littermate controls for the AD study (WT/ChGFP).  
Tthese WT/CHGFP mice were used separately for analysis of BFCNs in the 6-
month old to 24-month old aging profile.   
 
Tissue Processing 
Mice were euthanized with CO2 and decapitated.  Brains were placed in an ice-
cold metal brain mold containing 1 mm slots.  The medial septum along with the 
vertical and horizontal diagonal bands of Broca was isolated by cutting a 2 mm 
section rostral to the optic chiasm. The remaining frontal cortex and olfactory 
bulbs, rostral to the septal slice, were bisected down the midline and then 
dissected to isolate each region.  The remaining caudal tissue, was bisected 
down the midline.  The left olfactory bulb, left frontal cortex, left hippocampus 
was placed into small eppendorf tubes on dry ice and then stored at -70°C for 
biochemical analysis.  The right olfactory bulb, right frontal cortex and right hemi-
brain were drop fixed in 4% paraformaldehyde, 75 mM lysine, 10 mM sodium 
periodate; pH 7.4 solution for 24 hours at 4 °C and subsequently  cryoprotected 
in a 10% glycerol/2%DMSO solution in 0.1M phosphate buffered saline (PBS, pH 
7.4) for 24 hours, afterward the tissues were placed into 20% glycerol/2%DMSO 
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in 0.1M PBS solution and stored at 4°C. The 2 mm forebrain slice containing the 
basal forebrain and the right hemi-brain containing the hippocampus, were 
serially sectioned in the coronal plane on a freeze sliding microtome at 40 μm.  
Free floating sections were then stored in 0.02% sodium azide solution in 0.1M 
PBS at 4°C. 
Immunofluorescence   
For Aβ42 immunofluorescence, free floating sections were removed from 0.02% 
sodium azide/PBS storage solution and rinsed with PBS.   First, the sections 
were incubated for 3 hr in a blocking buffer solution consisting of 10% normal 
donkey serum and 0.3% Triton X-100 in PBS.  The sections were then incubated 
overnight with an antibody buffer solution of 1% BSA, 0.3% Triton X-100 in PBS 
supplemented with recombinant affinity-purified, primary rabbit anti-Aβ42 
monoclonal antibody (Life Technologies, 1:2500; cat.# 700254).  The next day, 
sections were rinsed with PBS, blocked in the aforementioned blocking buffer for 
3 hrs then incubated in the dark for 6 hrs in the antibody buffer solution 
supplemented with secondary Alexa Fluor-594 donkey anti-rabbit IgG or donkey 
anti-goat IgG antibody (Life Technologies,1:1000).  After the final PBS rinse, the 
sections were allowed to dry on SuperfrostPlus slides (Fisher) then coverslipped 
with VectaShield and allowed to dry at room temperature in the dark, afterwards 
the slides were stored at -20 °C.  Each PBS rinse step consisted of 3-10 min 
washes and all rinses and incubations were performed at room temperature on a 
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rotating shaker.  No Aβ42 fluorescence was observed in wild-type mice or in 
APP/PS1dE9 mice incubated with secondary antibody alone.   
For PrPc and p75/NTR immunostaining, tissue sections were washed in PBS (pH 
7.4), incubated in blocking buffer solution consisting of 1%BSA and 0.3% Triton 
X-100 in PBS for two hours to reduce nonspecific binding.  Goat anti-mouse PrPc  
primary antibody (1:750, Abcam) or rabbit anti-mouse p75/NTR primary antibody 
(Millipore, 1:500) were added to an antibody buffer solution of 10% appropriate 
serum, 0.3% Triton X-100, 0.02% sodium azide in 0.1 M PBS and the sections 
were incubated overnight at room temperature on a rotating shaker.  Sections 
were rinsed in PBS and blocked in the aforementioned blocking buffer for 2-3 
hours.  Sections were then incubated for 6 hr in the dark on a shaker at room 
temperature, in the aforementioned antibody buffer solution containing secondary 
donkey anti-rabbit IgG (H+L) or donkey anti-goat IgG (H+L) conjugated to 
AlexaFluor-594 (1:1000, Molecular Probes).  After 3x10 min PBS rinses, the 
sections were incubated with DAPI (1:1000, Invitrogen) in 0.1M PBS for 10-15 
minutes on a shaker in the dark then washed for 15 minutes in PBS.  The 
sections were placed on subbed SuperFrostPlus slides (Fisher) and allowed to 
dry.  Sections were then mounted with ProLong Gold (Invitrogen) or VectaShield 
(Vector Labs) mounting media and coverslipped.  Slides were allowed to harden 
overnight at 4°C and then sealed with nail polish.   
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Confocal Microscopy 
Imaging was performed on an LSM710 NLO laser scanning confocal microscope 
(Zeiss) using Argon/Krypton and Helium/Neon lasers set to 488nm and 594nm, 
respectively.  Z-stack images of the entire MS, VDB and HDB were scanned.  
Imaging parameters such as pinhole size, detectors, and laser intensity were 
optimized and held constant in all experiments.  Minor heterogeneities from 
section to section were adjusted using gain and digital offset settings.   To 
minimize crosstalk and bleed-through during imaging, each fluorescent signal 
was imaged in sequential scanning mode with an EC-Plan NeoFluar 40x/1.30 Oil 
DIC M27 objective (Zeiss).   
Image Analysis 
PrPc Quantification 
Three coronal sections from 8 female mice (WT; n=4, APP/CHGFP; n=4) 
spanning the basal forebrain were selected for semiquantitative analyses of PrPc 
expression in ChAT+ cell bodies.  Images were coded and counted in a blinded 
fashion.  In Volocity 3D image analysis software (Perkin Elmer), the orthoslice 
tool was used to determine the total number of BFCNs expression PrPc in the X-
Z and Y-Z dimension as shown in Figure 19.  Statistical analysis performed with 
SYSTAT by one-way ANOVA. Data are presented as mean ± SEM.  
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Hippocampal Cholinergic Fiber Quantification after BMP9 Treatment 
All fluorescence imaging of cholinergic fibers and amyloid plaques was 
performed on an LSM710 laser scanning confocal microscope (Zeiss) with an 
EC-Plan NeoFluar 40x/1.30 Oil DIC M27 oil immersion objective at 1.2x optical 
zoom for final magnification of 48x.  Laser settings were optimized and held 
constant as follows: laser intensity, 2% for Alexa-Fluor 488 and 594; 
aperture/pinhole, 1.23AU; averaging speed, 4; scan speed, 6; image resolution, 
512 x 512.  For every mouse (n=29) belonging to one of four groups (APP/BMP, 
n=7; APP/PBS, n=7; WT/BMP, n=8; WT/PBS, n=7) two coronal hippocampal 
sections (1 anterior, 1 posterior) were imaged.   A total of 263, 10μm z-stacks 
taken at 1μm intervals were scanned in the hilus of the DG or the stratum 
radiatum layer of CA1, CA2, and CA3.  Images were coded by an individual 
blinded to the experimental parameters and then transferred to Volocity® 3D 
analysis software (PerkinElmer).    An empirically optimized batch protocol 
function was established to: 1) find objects of interest using threshold intensities 
between 20-255, and 2) exclude objects less than 0.3μm3 and greater than 
100μm3.    The batch protocol was then automatically applied to all images and 
the total object volume (in μm3) per image/per individual was then exported to an 
Excel spreadsheet.  After a human operator “data-validation” step to confirm 
Volocity® object recognition [see (Piltti et al., 2011)], a total of 8 images (of 263) 
required manual correction.  Object volumes were accepted as an index of 
cholinergic fibers present in the hippocampus.  Statistical analysis of differences 
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in cholinergic fiber volumes between genotype- and BMP9 treatment groups was 
performed with SigmaPlot software by two-way ANOVA. Data are expressed as 
mean ± SEM. 
 
RESULTS 
The aim of these experiments was to test the utility of confocal microscopy 
to image cholinergic neurons and cholinergic nerve fibers in transgenic mice 
engineered to express enhanced green fluorescent protein in cholinergic cells.  
These techniques were applied to studies of aged mice (Figure 4) as well as 
mice engineered to develop the pathological changes associated with AD for the 
purpose of understanding the molecular and morphological changes incurred by 
the basal forebrain cholinergic system during these two processes.  In order to 
study the effects of BMP9 infusion on AD-like pathology, we studied animals at 
10-months of age because they display significant amyloid deposition, reduced 
ChAT activity and BFCN impairments exemplified by neuritic plaques and 
dystrophic neurites in the cholinergic projection targets of the hippocampus and 
cerebral cortex (Perez et al., 2007).   
 
BMP9 INFUSION IMPROVES AD-LIKE PATHOLOGY IN VIVO 
 We imaged GFP-positive cholinergic fibers in the hippocampus using laser 
scanning confocal microscopy and quantified z-stacks in the hippocampal areas 
of the stratum radiatum moleculare of CA1, CA2, CA3 fields and in the hilus of 
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the dentate gyrus.  This analysis revealed that BMP9 infusion significantly 
increased cholinergic fiber densities in WT/CHGFP and APP/CHGFP mice for 
the combined regions of interest through the hippocampus (Figure 12) and 
separately within the CA1-stratum radiatum moleculare and hilus of the dentate 
gyrus (Figures 13A & B).  BMP9 infusion dramatically increased ChAT protein in 
APP/PS1 mice above normal WT levels in the HPC as detected by ELISA and 
also induced modest but significant increases of hippocampal NGF and NT-3 
protein expression levels (Burke et. al, manuscript in preparation).  These data 
provide further evidence that BMP9 supports a neurochemical niche sufficient for 
BFCN trophic support and may represent a therapy for AD patients by increasing 
cholinergic neurotransmission to potentially maintain memory or cognitive 
performance. 
 The observed increase in hippocampal cholinergic density could be 
attributed to increased axonal branching of existing cholinergic neurons.  One 
interesting observation is that BMP9 increased NT-3 levels which has been 
shown to increase synaptic connections during development by promoting 
cholinergic branching and axonal extention to the hippocampus and cerebral 
cortex (Robertson et al., 2006).  A qualitative analysis of BMP9 vs. PBS infused 
WT/CHGFP mice support the notion of increased cholinergic extentions and 
possibly branching  mediated by neurotrophin signaling possibly via NT-3 (Figure 
14).  
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Figure 12  Quantification of total hippocampal cholinergic fiber densities 
within the stratum radiatum moleculare (SR) region of CA1, CA2, CA3 and in 
the hilus of the dentate (hDG) gyrus among the four groups, expressed as 
mean ± SEM.   
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Cholinergic fibers avoided Aβ42 plaques and in PBS-infused APP/CHGFP mice 
neuritic plaques and dystrophic neurites were prominent as previously described 
by (Perez et al., 2007).  APP/CHGFP mice that received BMP9 infusion 
displayed fewer dystrophic neurites adjacent to Aβ42 plaques, as depicted in 
Figure 15 and there was an enhancement in the cholinergic fiber network in 
these animals.  Visualizaton of Aβ42 immunofluorescence at higher 
magnifications revealed numerous, diffuse plaques as well as large plaques in 
the hippocampus of PBS-infused mice while BMP9 infused mice contained 
mostly large, dense plaques. As Aβ42 is more hydrophobic than Aβ40, it is 
postulated that its oligomers are the most toxic Aβ species (Selkoe, 1997).   
 
Figure 13  (Next two pages)  Confocal images from each of the four 
experimental groups and a scatter plot (n=27) of the cholinergic densities in 
the hilus of the dentate gyrus (A) and CA1/stratum radiatum (B) regions of 
the hippocampus.  This analysis revealed that BMP9 effectively increased 
cholinergic innervation to the hippocampus of WT/CHGFP and APP/CHGFP 
mice. Red bars are the mean for each group; scale bar, 50 μm.  
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Figure 14  Cholinergic neurites in the granular layer of  CA1 
appeared longer in WT/CHGFP mice infused with BMP9 versus 
PBS (40x). 
PBS  BMP9 
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Figure 15  Confocal images of immunofluorescent staining of Aβ42 (red) in the 
hippocampus also showing disrupted cholinergic network (green).  PBS-
infused (controls) contained weak, inconsistent fibers and more dystrophic 
neurites (white arrows) whereas BMP9 infusion ameliorated these cholinergic 
deficits in APP/CHGFP animals. 
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The apparent BMP9 mediated reductions in the number of smaller, diffuse 
plaques may effectively reduce the total plaque surface area and minimize 
disruptive Aβ42 interactions with proteins of essential function.  The mechanism 
by which BMP9 reduces Aβ42 plaque burden is a prospect for further research to 
determine whether BMP9 reduces plaque deposition or increases plaque 
clearance.  The ability of BMP9 to induce exuberant cholinergic growth in the 
hippocampus of an AD-like model compels future studies to determine if the 
improved cholinergic network improves cognition in the APPswe/PS1dE9 mice.  
This could be achieved using well characterized cognitive-behavioral assays, e.g. 
the Barnes maze to test spatial memory capabilities of the mouse to locate a 
dark escape box for safety, or the Morris water maze which also measures 
visuospatial memory as a function of latent time to locate a platform and escape 
from the stress of swimming.  
 These data demonstrate that administration of BMP9 ameliorates two 
overt pathophysiological components of AD by reducing amyloid plaque burden 
and by increasing the ChAT-positive cholinergic network in the hippocampus.  
 
BFCN GENE EXPRESSION IN APP/CHGFP MICE 
 
 Of approximately 30,000 genes in the human  genome, different cell types 
express only an individual subset of these genes which permit their specification 
and function.  Cells that are selectively affected by disease, are known to 
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undergo homeostatic or pathologic changes in gene expression, a paradigm that 
may provide diagnostic value or biomarker identification and/or medical targets of 
therapy.   
 The molecular analysis of specific cell types in the brain is hampered by 
the brain’s heterogeneity of densely packed neuronal subclasses and glial cells.    
Furthermore, a given neuronal population within a specific brain region likely 
represents a minority subset of cells within that region.  Despite this, whole cell 
populations dissociated from a resected area of the brain have enabled a variety 
of in vitro studies of cell-function and cell-cell interactions but a thorough 
transcriptomic analysis of a specific cell type remains challenging with this 
methodology.  Importantly, fluorescence-activated cell sorting (FACS) has been 
used to identify subsets of cells in mixed populations.  This technique has 
provided major advances in cancer and immunology research but is underutilized 
in studying the CNS.  Originally, a method for the generation of healthy, purified 
BFCN cultures by FACS using a fluorescent antibody against p75/NTR produced 
cultures enriched in the cholinergic markers p75/NTR, ChAT and ChT (Schnitzler 
et al., 2008a).  This method  has been simplified with the use of transgenic mice 
expressing GFP from the ChAT promoter and can be a powerful tool for purifying 
BFCNs to study their gene expression profiles in normal, aging and diseased 
states.   
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Figure 16  FACS purified BFCNs from WT/ChAT-eGFP.  Note: 3.7% of 
cells from E18 mice septae express ChAT-eGFP and these cells have 
enriched mRNA expression levels for BFCN markers; Chat, p75, Cht.  
Loading control: Actb; beta-actin.  Adapted from: A.C. Schnitzler et. al, 
J. Neurosci. (2010). 
 61 
To study the gene expression profile of BFCNs in the APPswe/PS1dE9, a mouse 
model with AD-like pathology, the septal region was harvested from 6 month old 
WT/CHGFP and APP/CHGFP mice expressing GFP from the ChAT promoter.  
BFCNs constitute approximately 3-5% of the entire cell population in the septum 
as indicated in Figure 16 and previous experiments.  
FACS purified BFCN mRNA was extracted using the guanidinium-
thiocyanate-phenol/chloroform method, after a cRNA amplification step and a 
spiked standard curve was used to normalize RNA frequencies. Next, mRNA 
reaction mixtures from WT/CHGFP and APP/CHGFP BFCNs obtained by FACS 
were enriched in mRNA for the cholinergic markers p75/NTR, ChAT and ChT 
and then subjected to Affymetrix Mouse Genome 430 2.0.  These arrays were 
stained with Streptavidin R-phyocoerythrin using the GeneChip Fluidics Station 
400 and scanned with a Hewlett-Packard GeneArray Scanner.  The data 
collected was then analyzed by Microarray Suite 4.0 software.   
 This analysis identified some 300 differentially expressed genes in 
WT/CHGFP and APP/CHGFP mice BFCNs which clearly formed separate 
clusters as shown in Figure 17.   Some of these genes as shown in Figure 18 
have been previously implicated in the pathophysiology of AD and amyloidosis.  
In particular one of these genes is LIMK1.  
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LIMK1 mRNA levels were reduced 50% below WT expression levels.  LIMK1 is 
cytoplasmic protein kinase regulating cytoskeletal structure and function and is 
important during neurodevelopment by promoting axonal extention.  It is very 
interesting that LIMK1 has been shown to directly interact with the BMP type II 
receptors to deregulate actin dynamics (Foletta et al., 2003).  LIMK1 also 
interacts with neuregulins which are known to be important for the development 
of hippocampal-dependent visuospatial cognition (Wang et al., 1998). 
Furthermore, inhibition of Aβ-induced LIMK1 phosphorylation of Cofilin with a 
specific peptide competitor abrogated hippocampal neuronal dystrophy and 
degeneration (Heredia et al., 2006).   
 In light of these data, our observation that LIMK1 mRNA is reduced in 
BFCNs of AD-like mice may validate the use of this model to advance the study 
of human AD, since as altered levels of phospho-LIMK1 have been reported in 
human brain regions affected by AD (Heredia et al., 2006).  
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Figure 17  Gene expression analysis with 
Affymetrix microarrays in FACS-purified 
BFCN from 6 month old wild type (WT) and 
APP.PS1 male mice.  Graphical 
representation of cluster analysis of 300 
differentially-expressed genes is shown.  
Note that the WT and APP.PS1 BFCN 
genes organize into clearly separate 
clusters. 
 64 
 
 
 
 
 
 
  
0
25
50
75
100
125
150
175
Limk1 Map2 Capn2 Il33 Notch3
m
R
N
A
 l
e
v
e
ls
, 
%
 o
f 
w
ild
 t
y
p
e WT
APP.PS1
FIGURE 18 Candidate genes with differential mRNA expression in BFCN purified 
from 6-month old APP.PS1 male mice as compared with the WT littermates.  
APP/PS1 mRNA expression levels in the graph above were normalized to WT 
expression levels derived from Figure 17. 
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PrPc IS UPREGULATED IN BFCNs OF APP/CHGFP MICE 
 
 The mRNA coding for the cellular prion protein (PrPc) was observed to be 
upregulated in BFCNs of APPswe/PS1dE9 mice.  PrPc is a glycosyl 
phosphatidylinositol (GPI) anchored-cell surface protein which localizes to lipid 
rafts in the extracellular leaflet of the plasma membrane.  It is expressed in the 
peripheral tissues as well as in neuronal cell bodies and at post-synaptic 
densities.  In its misfolded form, PrPc is converted to amyloidogenic PrPSc and is 
responsible for the fatal neurodegenerative disorders classified as transmissible 
spongiform encephalopathies, including Creutzfeldt-Jakob disease, kuru and 
Gersmann-Straussler-Scheinker syndrome (Prusiner and DeArmond, 1990)).  
Also, a D178N mutation and homozygosity for methionine at PrPc codon 129 are 
known to cause fatal familial insomnia (Montagna et al., 2003).  Interestingly, a 
single nucleotide polymorphism that causes a M129V mutation in PrPc has also 
been associated with late-onset Alzheimer’s disease (Gunther and Strittmatter, 
2010).  
Much more is known about the pathogenic actions of PrPc however new 
research is beginning to shed light onto the physiological roles of this protein. 
PrPc functions as a copper-dependent NMDA-R ion channel regulator (You et al., 
2011), as a cell adhesion molecule by interacting with integrins, NCAM and 
laminin, as reviewed in (Biasini et al., 2012) and as a.  It has been argued that Aβ 
oligomers are dependent on PrPc expression to mediate LTP inhibition and 
 66 
synaptic dysfunction in pyramidal neurons of the hippocampus (Gimbel et al., 
2010), whereas the physiological and pathological function of PrPc expression 
within BFCNs is largely unknown.  Research has demonstrated two possible 
ways that Aβ/PrPc interactions can cause excitotoxicity in neurons.  First, Aβ 
treatment of dissociated GABAergic and cholinergic forebrain neurons caused 
reductions in calcium-activated potassium conductance in a PrPc dependent 
fashion (Alier et al., 2011).  This scenario could effectively reduce the refractory 
period of membrane repolarization, extend action potentials and excitability and 
facilitate BFCN excitotoxicity.   Secondly, coimmunoprecipation of PrPc with 
NR2D subunits of NMDA receptors suggests a direct interaction with this 
glutamate activated non-selective cation channel.  Hippocampal neurons treated 
with copper chelators, Aβ42 or PrP
c inactivation resulted in nondesensitized 
NMDA-induced currents and neurotoxicity (You et al., 2011).  This suggests that 
PrPc may normally modulate ion channels concentrated at synapses whereas Aβ 
binding to PrPc interferes with this essential regulatory function preventing 
excitotoxicity.  Interestingly, PrPc has been shown to undergo α- and γ-secretase 
cleavage, similar to APP (Checler, 2012) and provides further evidence for 
common mechanisms in neurodegenerative diseases.   
Previous members in our lab enabled the microarray analysis of BFCN 
mRNA (Schnitzler et al., 2008a).  This analysis implicated PrPc as a gene 
displaying a dysregulated expression profile in the APPswe/PS1dE9 mouse 
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model of AD.  BFCNs from 6-month old APP/CHGFP mice exhibited a 2.8-fold 
increase in PrPc mRNA levels as compared to WT/CHGFP BFCNs (p = 0.02).   
In light of this, we sought to determine the percentage of CHATGFP-
positive BFCNs expressing PrPc protein using semi-quantitative 
immunofluorescence and laser scanning confocal microscopy.  After 
immunofluorescence and imaging, the Volocity software orthoslice tool was used 
to quantify the total number of of cholinergic neurons in the basal forebrain and in 
the striatum that coexpressed PrPc as illustrated in Figure 19.    
The striatum (STR) is a forebrain region associated with planning, 
anticipating and modulating pathways that control movement and procedural 
memory.  The striatum is comprised of medium spiny neurons (96%), Dieter’ 
neurons (2%), parvalbumin-, calretinin-, somatostatin-positive GABAergic 
interneurons as well as cholinergic interneurons (1%). Cholinergic interneurons in 
the striatum did not demonstrate any major difference in PrPc protein expression 
among APP/CHGFP as compared to WT/CHGFP mice.  At older ages, the 
APPswe/PS1dE9 mice develop overt cholinergic deficits and Aβ-plaque 
deposition the striatum (Perez et al., 2007).  Consistent with these reports, we 
did not see any amyloidosis in the striatum of these 8 month old mice, however 
signs of cellular blebbing and dystrophic cholinergic neurons in the striatum were 
observed at this time point.  This result suggests that cholinergic degeneration in 
the striatum may precede Aβ deposition which points to trophic withdrawal, 
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excitotoxicity or other uncharacterized mechanisms as the cause of cholinergic 
dysfunction.   
Consistent with other studies in mice and in humans, immunofluorescence 
for Aβ plaques did not reveal any staining in the MSN, VDB and HDB. However, 
the percentage of BFCNs expressing PrPc in these regions revealed a 46% 
increase in PrPc protein expression as shown in Figure 20.  The functional 
significance of increased PrPc expression in APPswe/PS1dE9 BFCNs remains to 
be determined although it provides fertile ground to study the role of PrPc as a 
possible pathogenic factor mediating cholinergic dysfunction in AD. 
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Figure 19  An orthoslice screenshot from the quantitative analysis 
procedure used to determine PrPc and ChATGFP overlap.  Sections 
through the basal forebrain cholinergic nuclei and striatum were 
immunostained for PrPc (red).  3D Z-stack images were imported to a 
Volocity library and analyzed in the X, Y, and Z planes using the 
orthoslice tool.  This analysis enabled counting of total number of 
neurons positive for both ChATGFP and PrPc in both the MS/VDB/HDB 
and the STR areas (40x objective). 
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DISCUSSION 
 
 These results support our underlying hypotheses that as a result of aging 
and AD,that BFCNs acquire altered morphological features, and BFCNs in AD 
display a differential gene-protein expression profile.  Secondly, we hypothesized 
that BMP9, an induction factor sufficient for BFCN differentiation in-vitro and in-
vivo, would support BFCN maintenance would promote BFCN growth and 
survivability, in a model of AD characterized by heavy Aβ-amyloidosis and a 
pronounced cholinergic deficit.  
Our data reveal that a 7-day BMP9 infusion induced an exuberant 
improvement in the cholinergic network in the hippocampus of WT/CHGFP and 
APP/CHGFP mice.  We detected a quantitative increase in cholinergic fiber 
density within the DG (hilus) and the stratum radiatum layers of CA1, CA2 and 
CA3 with BMP9 infusion. Consistent with previous reports, BMP9 also increased 
expression of the NGF receptors, p75/NTR and TrkA (data not shown; Burke et. 
al, manuscript in preparation).  BMP9 induced the BFCN phenotype and an 
optimized trophic environment for BFCNs by increasing levels of NGF and NT-3 
(Burke et. al, manuscript in preparation) which possibly contributed to the robust 
upregulation of cholinergic innervation in the hippocampus of APP/CHGFP mice.  
Since ACh neurotransmission acts as a neuromodulator, the regrowth and 
replacement of the exact cholinergic synapses may not be necessary to enhance 
memory and cognition (Bissonnette et al., 2011).   
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BMP9 infusion quantitatively reduced Aβ plaque levels in the anterior and 
posterior hippocampal sections of APP/CHGFP mice (Burke et. al, manuscript in 
preparation).  BMP9 also reduced the number of dystrophic cholinergic neurites 
surrounding Aβ plaques in the hippocampus and shifted plaque 
immunofluorescent staining patterns from scattered-diffuse to dense-compact 
plaque morphologies.  These data demonstrate that brains affected by AD-like 
amyloidosis may be primed for BMP9 signaling since a short 7-day infusion 
resulted in a dramatic increase in cholinergic fiber density and a reduction of Aβ 
in APP/CHGFP mice.  The data from this AD-like mouse model suggest that 
BMP9 may possess some therapeutic value to counteract the two major 
pathophysiological hallmarks of AD, Aβ -amyloidosis and the cholinergic deficit. 
With aging and AD, BFCNs undergo morphological changes.  
Qualitatively, we observed that BFCNs in 24-month old WT/CHGFP mice 
appeared to have retracted arborizations and their cell somas were more 
rounded in shape and smaller in size.  These alterations may be due to age-
induced disruptions of specific cytoskeleton networks leading to reduced stability, 
cell shrinkage and axonal retraction.  Not surprisingly, APP/CHGFP BFCNs were 
also observed to display smaller soma sizes and shorter projections as 
compared to healthy WT/CHGFP mice.  Based on the microarray data for 
APP/CHGFP BFCNs, proteins associated with cytoskeletal architecture appear 
to be involved in the AD-like pathophysiology affecting the form and function of 
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BFCNs. MAP2 mRNA was reduced by 50% and CAPN2 levels were increased 
by more than 75% in BFCNs from APP/CHGFP mice.   
Calpain 2 (CAPN2) is a calcium-activated neutral protease located to lipid 
rafts where it regulates cytoskeleton turnover by cleaving actin, microtubule-
associated proteins, spectrins and neurofilaments (Adamec et al., 2002).  CAPN2 
has been associated in a variety of neurodegenerative disorders including AD.  
Using confocal immunofluorescence, the active form of CAPN2 was shown to 
colocalize with 50-75% of hyperphosphorylated, neurofibrillary tau tangles 
(NFTs) in AD brain tissue (Adamec et al., 2002).  These studies as well as our 
microarray gene expression analysis of APPswe/PS1dE9 BFCNs implicate the 
proteolytic mechanism of CAPN2 as a potential driver of cytoskeletal disruptions 
of cholinergic morphology during AD-like pathophysiology.  
MAP2 is another cytoskeletal protein which crosslinks and stabilizes 
microtubules to microtubules and microtubules to intermediate filaments.  
Dendritic localized MAP2 and axonal localized Tau (MAPT) are in the same 
microtubule-associated protein (MAP) family and hyperphosphorylation of these 
proteins leads to microtubule destabilization, aggregation and NFT formation.  
The APPswe/PS1dE9 AD-like model do not produce NFTs whereas NFTs are a 
hallmark feature observed in post-mortem human AD brain tissue. 
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Figure 20  Representative images and quantification of PrPc expression 
(red) in BFCNs (green).  APP/CHGFP (APP.PS1) basal forebrain cholinergic 
neurons  reveal a significant increase in the percentage of BFCNs expressing 
PrPc as compared to WT/CHGFP BFCNs (p=0.007).  White arrows in upper 
panel indicate PrPc+ and CHATGFP+ cells.  Note that APP/CHGFP BFCNs 
(left, bottom panel) consistently appear smaller than WT BFCNs (left,top 
panel).   
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Based on PrPc mRNA levels from the microarray analysis, we compiled z-stacks 
of BFCNs expressing GFP and used a specific immunofluorescent staining to 
detect PrPc protein expression in BFCNs.  When compared to WT/CHGFP 
control littermates, the percentage of BFCNs in APP/CHGFP BFCNs expressing 
PrPc increased by 46% (Figure 20).   
 It should be noted that the engineered APPswe and PS1dE9 transgenes 
are under the transcriptional control of an upstream (Prnp) prion promoter in 
order to drive high transgene expression in the brain and highest expression is 
observed in the cortex and hippocampus (Perez et al., 2007) however our 
studies focused on the basal ganglia cholinergic nuclei in the medial septum and 
the diagonal bands of Broca.  It is highly unlikely that the integration of the 
exogenous Prnp promoter would increase the transcriptional activity of the 
endogenous promoter leading to increased PrPc mRNA or protein expression in 
basal forebrain cholinergic neurons.  Additionally, transcription preinitiation 
complexes formed by TFIIA, -IIB, -IID, -IIE, -IIF, -IIH and RNA polymerase II at 
transcription start sites specify basal level gene expression and are found to be 
in general abundance within the nucleus (Thomas and Chiang, 2006).  However 
specific coactivators and cofactors which fine-tune gene-specific promoter 
activity may be in shorter supply.  In this scenario, introduction of the exogenous, 
transgenic Prnp promoter could reduce the endogenous Prnp promoter activity 
and PrPc levels by roughly half.  Furthermore, there was no difference between 
PrPc expression in striatal cholinergic interneurons of WT and APPswe/PS1dE9 
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mice, indicating that PrPc up-regulation demonstrated some cell-type specificity.  
These data lead us to reason that the measured increase of PrPc expression in 
BFCNs is not due to the effects of the exogenous Prnp promoter but is a by-
product of the underlying pathophysiology that this AD model phenotypically 
expresses.    
 The upregulation of PrPc is interesting due to the fact that Aβ-PrPc was 
shown to inhibit synaptic plasticity in the hippocampus (Lauren et al., 2009).  Aβ 
binding to PrPc may interfere with its physiological functions at the synapse, such 
as NMDA-R regulation and cell adhesion or it may activate aberrant signaling 
cascades.  In support of this idea, two independent groups have proposed a 
pathologic mechanism for Aβ oligomer signaling via PrPc leading to activated 
FYN kinase (Larson et al., 2012; Um et al., 2012). Um et al, (Um et al., 2012) 
determined that oligomeric Aβ-PrPc-FYN kinase signaling reduced synaptic 
levels of NMDA-R/NR2B subunits, induced dendritic spine retraction and 
neuronal impairment. Larson et al, (Larson et al., 2012) used size exclusion 
chromatography to show that Aβ dimers from human AD brain extracts bind PrPc, 
leading to phosphorylation and activation of FYN kinase which resulted in tau 
phosphorylation and toxicity in vivo.    
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Figure 21  PrPc at the center of the AD Triad.   This proposed 
model shows how PrPc contributes to all three AD hypotheses.  
This model is based on results from multiple labs demonstrating 
the role of PrPc in various in-vitro and in-vivo experiments, 
however the contribution of PrPc to human AD is still uncertain. 
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We present the first examination of PrPc expression levels in BFCNs of 
this AD-like mouse model.  This increase in PrPc mRNA expression in 6-month 
old and PrPc protein levels in 8-month old APPswe/PS1dE9 mice suggests that 
PrPc upregulation may potentially be an early event during AD-like pathogenesis 
in this model.  
The relationship of PrPc to all three major AD hypotheses is especially 
intriguing.  The convergence of three pathophysiological mechanisms observed 
in AD onto PrPc implicates it as a target for AD treatment through the use of a 
small peptidomimetic competitor of Aβ-PrPc interactions which would be able to 
cross the blood-brain barrier.  Finally, PrPc is known to undergo proteolytic 
cleavage by ADAM17/TACE to generate an N1 terminal fragment that mediates 
neuroprotection (Checler, 2012).  Fluharty et al, have also demonstrated that this 
PrPc-N1 fragment binds Aβ to prevent neurotoxicity (Fluharty et al., 2013).  Since 
PrPc was elevated in the APPswe/PS1dE9 model of AD the next studies should 
investigate PrPc levels in basal forebrain cholinergic neurons of human AD brain 
samples to determine if this protein is relevant to human disease.  Since the 
upregulation of PrPc may also lead to increased N1 shedding, this 
neuroprotective fragment of PrPc could potentially be a biomarker of AD. 
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